# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Ed Arce reiterates Albireo Pharma (NASDAQ:ALBO) with a Neutral and maintains $42 price target.
Guggenheim analyst Seamus Fernandez downgrades Albireo Pharma (NASDAQ:ALBO) from Buy to Neutral.
Cowen & Co. analyst Ritu Baral downgrades Albireo Pharma (NASDAQ:ALBO) from Outperform to Market Perform and lowers the ...
Jefferies analyst Eun Yang downgrades Albireo Pharma (NASDAQ:ALBO) from Buy to Hold and lowers the price target from $49 to ...